Michelle Afkhami, MD, from City of Hope, discusses best practices for oncology organizations to leverage molecular/genomic testing, the importance of identifying RET-positive patients early so they can receive targeted treatment, and more.
Diagnostic testing in thyroid cancer is important in order to use biomarkers and quickly identify appropriate treatments for patients.
In this podcast, The American Journal of Managed Care®'s associate editorial director, Mary Caffrey, speaks with Michelle Afkhami, MD, from City of Hope, about best practices for oncology organizations to leverage molecular/genomic testing, the importance of identifying RET-positive patients early so they can receive targeted treatment, and more.
Listen above or through one of these podcast services: